Rapastinel FDA Approval Status
FDA Approved: No
Generic name: rapastinel
Previous Name: GLYX-13
Company: Naurex Inc.
Treatment for: Depression
Rapastinel (GLYX-13) is a novel NMDA receptor modulator in clinical development as an intravenous adjunctive therapy for major depressive disorder (MDD).
Development timeline for rapastinel
| Date | Article |
|---|---|
| Mar 3, 2014 | FDA Grants Fast Track Designation to Naurex's Rapid-Acting Novel Antidepressant GLYX-13 |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.